Meeting
2017 ASCO Annual Meeting
Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer.
Authors
Panagiotis A. Konstantinopoulos
Dana-Farber Cancer Institute, Boston, MA
Panagiotis A. Konstantinopoulos , Joyce F. Liu , William Thomas Barry , Carolyn N. Krasner , Mary K. Buss , Michael J. Birrer , Sarah Farooq , Susana M. Campos , Elizabeth Stover , Susan Schumer , Alexi A. Wright , Jennifer Curtis , Ariana Peralta , Christin Whalen , Don S. Dizon , Richard T. Penson , Stephen A. Cannistra , Gini F. Fleming , Ursula A. Matulonis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT02912572
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS5615)
DOI
10.1200/JCO.2017.35.15_suppl.TPS5615
Abstract #
TPS5615
Poster Bd #
429b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee
Poster
2023 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee
Poster
2021 ASCO Annual Meeting
Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
First Author: Wei Wei
Poster
2017 ASCO Annual Meeting
An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma.
First Author: Assuntina Gesualda Sacco